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SYSTEMATIC REVIEW AND META- ANALYSIS
Network Meta- Analysis Comparing the 
Outcomes of Treatments for Intermittent 
Claudication Tested in Randomized 
Controlled Trials
Shivshankar Thanigaimani, PhD; James Phie, PhD; Chinmay Sharma; Shannon Wong; Muhammad Ibrahim; 
Pacific Huynh , PhD; Joseph Moxon, PhD; Rhondda Jones, PhD; Jonathan Golledge , MChir
BACKGROUND: No network meta- analysis has considered the relative efficacy of cilostazol, home exercise therapy, supervised 
exercise therapy (SET), endovascular revascularization (ER), and ER plus SET (ER+SET) in improving maximum walking dis-
tance (MWD) over short- (<1 year), moderate- (1 to <2 years), and long- term (≥2 years) follow- up in people with intermittent 
claudication.
METHODS AND RESULTS: A systematic literature search was performed to identify randomized controlled trials testing 1 or 
more of these 5 treatments according to Preferred Reporting Items for Systematic Review and Meta- Analysis guidelines. The 
primary outcome was improvement in MWD assessed by a standardized treadmill test. Secondary outcomes were adverse 
events and health- related quality of life. Network meta- analysis was performed using the gemtc R statistical package. The 
Cochrane collaborative tool was used to assess risk of bias. Forty- six trials involving 4256 patients were included. At short- 
term follow- up, home exercise therapy (mean difference [MD], 89.4 m; 95% credible interval [CrI], 20.9– 157.7), SET (MD, 
186.8 m; 95% CrI, 136.4– 237.6), and ER+SET (MD, 326.3 m; 95% CrI, 222.6– 430.6), but not ER (MD, 82.5 m; 95% CrI, −2.4 
to 168.2) and cilostazol (MD, 71.1 m; 95% CrI, −24.6 to 167.9), significantly improved MWD (in meters) compared with controls. 
At moderate- term follow- up, SET (MD, 201.1; 95% CrI, 89.8– 318.3) and ER+SET (MD, 368.5; 95% CrI, 195.3– 546.9), but not 
home exercise therapy (MD, 99.4; 95% CrI, −174.0 to 374.9) or ER (MD, 84.2; 95% CrI, −35.3 to 206.4), significantly improved 
MWD (in meters) compared to controls. At long- term follow- up, none of the tested treatments significantly improved MWD 
compared to controls. Adverse events and quality of life were reported inconsistently and could not be meta- analyzed. Risk 
of bias was low, moderate, and high in 4, 24, and 18 trials respectively.
CONCLUSIONS: This network meta- analysis suggested that SET and ER+SET are effective at improving MWD over the moder-
ate term (<2 year) but not beyond this. Durable treatments for intermittent claudication are needed.
Key Words: cilostazol ■ endovascular revascularization ■ exercise therapy ■ intermittent claudication ■ maximum walking distance 
■ network meta- analysis ■ peripheral artery disease
Intermittent claudication is a common cause of walking impairment, reduced health- related qual-ity of life (QOL) and low physical activity.1 The 
main treatment options for intermittent claudication 
are the medication cilostazol, supervised exercise 
therapy (SET), home exercise therapy (HET), and 
endovascular revascularization (ER).2 Despite a 
number of randomized controlled trials, systematic 
reviews, and traditional and network meta- analyses 
(NMA), there remains controversy regarding the most 
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appropriate therapy.3– 6 Assessment of the available 
evidence regarding the most effective treatment for 
intermittent claudication is difficult because of the 
absence of head- to- head comparison of all available 
therapies in 1 trial or in previous meta- analyses.3– 5 
Most randomized clinical trials have included a small 
number of participants or involved a limited number 
of the available therapies, meaning standard meta- 
analyses are not ideally suited to testing the most 
effective treatment. NMA have been designed to 
combine all available evidence for randomized trials, 
including treatments not compared head to head. A 
number of prior NMA have compared treatments for 
intermittent claudication but these have been sub-
ject to a number of limitations.4,7– 9 These include not 
incorporating all available treatments options, not 
examining outcomes at different follow- up times, 
and including therapies, such as older endovascu-
lar approaches, which are not contemporary.4,7– 9 
Assessing long- term, as well as short- term outcomes 
is important because recent evidence suggests that 
both exercise therapy and endovascular revascular-
ization are not durable.6,10 Furthermore, long- term 
results from 1 clinical trial have been reported since 
the publication of the most recent NMA and need to 
be incorporated into the available evidence.11 In order 
to address these limitations this NMA examined data 
from randomized controlled trials published in the 
past 2 decades that tested cilostazol, exercise ther-
apy, and ER for treating intermittent claudication.
METHODS
All data used in this study are available in the article 
and supplementary files.
Search Strategy
The systematic review was performed according to 
the Preferred Reporting Items for Systematic Review 
and Meta- Analysis with an extension for NMA state-
ment (PRISMA- NMA) and the study protocol was reg-
istered in the PROSPERO (International Prospective 
Register of Systematic Reviews) database (Registration 
Number: CRD42020197141). The literature search was 
conducted by 1 author (S.T.). The databases PubMed 
(Medline), Cochrane Central Register for Controlled 
Trials, and Web of Science were searched on April 21, 
2020. The full search strategy included terms related 
to intermittent claudication, treatment, and walking ca-
pacity (Data S1).
Study Selection
Randomized controlled trials testing cilostazol, SET, 
HET, ER and combination of any of these strate-
gies for treating intermittent claudication were eligi-
ble for inclusion. Control patients were defined as 
those under attention control, best or optimal medi-
cal treatment alone, or receiving placebo. HET was 
defined as either written exercise advice or a struc-
tured program consisting of exercise sessions that 
were mainly performed without supervision at home. 
SET was defined as an exercise program performed 
under direct supervision of a trained health profes-
sional. ER was defined to include angioplasty, stent-
ing, or related endovascular procedures. All included 
trials had to report maximum walking distance (MWD) 
measured in meters during a standardized treadmill 
test. Trials that were published as full texts or ab-
stracts were eligible for inclusion if the minimum data 
requirement (MWD at entry and at least 1 follow- up 
time) was published or available from the corre-
sponding author. When multiple publications arising 
from the same clinical trial were identified, data for all 
applicable time points were included. Trials published 
CLINICAL PERSPECTIVE
What Is New?
• This network meta- analysis of randomized 
controlled trials suggested that home exercise 
therapy, supervised exercise therapy, and a 
combination of supervised exercise therapy 
with peripheral revascularization significantly 
improved walking distance in patients with in-
termittent claudication over the short term com-
pared with controls.
• None of the tested treatments improved walking 
distance significantly compared with controls in 
the longer term.
What Are the Clinical Implications?
• Larger and better designed clinical trials test-
ing treatments for intermittent claudication are 
needed.
Nonstandard Abbreviations and Acronyms
CrI credible interval
ER endovascular revascularization
HET home exercise therapy
MCMC Markov Chain Monte Carlo
MD mean difference
MWD maximum walking distance
NMA network meta- analysis
SET supervised exercise therapy
SF- 36 36- Item Short Form Health Survey
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in languages other than English, nonrandomized or 
crossover trials, and observational studies and trials 
where baseline and at least 1 follow- up time point 
MWD were not available were excluded. In order to 
compare contemporary treatments, because of the 
substantial evolution in the techniques used for end-
ovascular revascularization over time, trials published 
before 2000 were excluded. Unpublished studies 
and abstracts where minimum data were not availa-
ble were also excluded. Eligibility was determined by 
2 authors (S.T. and J.P.), with discrepancies resolved 
by discussion with the senior author (J.G.).
Data Extraction
Primary outcome data were extracted on a custom-
ized spreadsheet by 2 authors (S.T. and S.W.) and 
findings were validated by 2 authors (J.P. and M.I.). 
Secondary outcomes were extracted by 2 authors 
(S.T. and P.H.) and the data were validated by 1 author 
(J.P.). Study characteristics were extracted by 3 au-
thors (S.T., J.P., and C.S.). Any inconsistencies were 
resolved through discussion and confirmed with the 
senior researcher (J.G.). The primary outcome was 
MWD (in meters) measured in a standardized tread-
mill test. In trials that did not report MWD, other data 
including peak walking time, absolute claudication 
distance, or maximum walking time were used to de-
rive MWD considering the type of treadmill test used. 
Secondary outcomes included QOL and serious ad-
verse events (SAE). Because multiple different QOL 
questionnaires were used in the included trials, it was 
not possible to perform a pooled analysis. QOL data 
were tabulated and findings reported qualitatively. 
SAEs were reported as the numbers of patients who 
had a myocardial infarction, stroke, events requiring 
hospital admission, lower limb revascularization, any 
other vascular procedure, any amputation, or death. 
In patients who were randomized to ER, only sec-
ondary lower limb revascularization procedures were 
considered as SAEs. The following additional data 
were extracted from the included trials: age, sex, 
body mass index, smoking, hypertension, diabetes 
mellitus, ankle brachial pressure index, medications, 
sample size, type of treadmill test, design of HET or 
SET program, type of ER, and duration of follow- up. 
Primary outcome data were categorized depending 
on the follow- up time as <1 year (short- term follow-
 up), ≥1 to <2  year (moderate- term follow- up), and 
≥2 year (long- term follow- up). Mean difference (MD) 
was calculated as the difference in mean values 
between the specified follow- up and baseline. SD 














Pearson correlation coefficient (Corr in the formula) 
was calculated using individual participant data from 
1 trial13 as used previously.14 The relative effect was 
expressed as MD±95% credible interval (CrI). CrI 
denotes the predictive distribution or interval within 
which a potential unobserved fixed effects parameter 
value could fall with a particular probability. CrI is the 
Bayesian statistics equivalent of CI. The statistical 
analyses were overseen by a senior researcher (J.M.) 
and the network model was validated by another 
senior researcher with extensive statistical expertise 
(R.J.).
Statistical Analysis
The Bayesian random effects NMA was performed 
using the R statistical package gemtc, which uses the 
arm- based model and provides effect size estimates 
for multiple comparisons.15 The package was available 
through R studio version 3.4.4 from the Comprehensive 
R Archive Network (CRAN) at https://cran.r- proje ct.org/
web/packa ges/gemtc/ index.html. The package con-
tains functions that use Just Another Gibbs Sampler, 
a program for analyzing Bayesian hierarchical models 
using Markov Chain Monte Carlo (MCMC) simulation.16 
The gemtc package uses Just Another Gibbs Sampler 
software to develop a random effects model assum-
ing consistency with variance scaling factor of 2.5 and 
noninformative normal prior distribution. Between- trial 
SDs were assumed to follow a noninformative uniform 
distribution and a weakly informative prior distribution. 
MCMC simulations were run using 3 chains with differ-
ent initial values for 100 000 iterations. Convergence 
of the resulting model was assessed using trace 
plots. Data were presented according to short- term, 
moderate- term, and long- term follow- up periods. 
Network diagrams of all available treatments from the 
included trials were plotted to compare and illustrate 
multiple treatment arms at different follow- up times. 
MCMC simulations were performed to estimate the 
posterior distributions of MWD data between different 
arms by running the simulations long enough to reach 
accurate estimates for the model. Convergence of 
the network models derived from MCMC simulations 
were assessed using trace and density plots. The sta-
bility of the MCMC simulation output was tested with 
Gelman- Rubin- Brooks plots and diagnostics were 
performed to determine Potential Scale Reduction 
Factor score. A Potential Scale Reduction Factor score 
of <1.05 is suggestive of good convergence in the net-
work model. Inconsistencies within the network model 
were assessed using a more sophisticated node split 
method; which estimates the random effects of differ-
ent comparison arms when using direct alone, indirect 
alone, and all available network evidence separately.17 
Any significant differences in estimates between direct 
and indirect evidence were considered as potential 
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probability was calculated for all available treatment 
strategies for each follow- up time.18 A P value of ≤0.05 
was considered as statistically significant.
Risk of Bias Assessment
Two authors (S.T. and J.P.) independently assessed the 
risk of bias of all included trials using the Cochrane 
Collaboration’s tool, which assessed key aspects of 
the reports including random sequence generation, 
statistical sample size estimate, the number of patients 
who completed the study, the primary outcome, blind-
ing of outcome assessors, intent- to- treat principle, and 
other biases.19 Quality parameters were marked as (+), 
(– ), and (?) for positive, negative, and unclear risk of 
bias respectively. Any study having 3 or more negative 
quality assessments were considered to have high risk 
of bias. Trials with 1 to 2 negative quality assessments 
were considered to have moderate risk of bias and 
those with no negative quality assessments were con-
sidered to have low risk of bias. Any inconsistencies 
were resolved through discussion between the authors 
until a consensus was reached.
RESULTS
Included Trials and Participants
After screening 46 clinical trials involving a total of 
4256 patients were included (Figure 1). Forty- two trials 
involving 3515 patients reported MWD (in meters) at 
short- term follow- up.6,13,20– 59 Fourteen trials involving 
1327 patients reported MWD (in meters) at moderate- 
term follow- up6,43,50– 54,56– 62 and 6 trials involving 601 
patients reported MWD (in meters) at long- term follow-
 up.6,54,55,57,62,63 Details such as the specific treatment 
strategy and outcome assessments are shown in 
Table  S1. The baseline characteristics of the partici-
pants are shown in Table 1.
Quality Assessment
A total of 4 clinical trials including 2 trials comparing 
SET versus ER,52,59 and 1 trial comparing cilostazol 
versus control,46 and 1 trial comparing HET and 
SET51 were deemed to have low risk of bias, 24 trials 
had moderate risk of bias,* and 18 trials were consid-
ered to have high risk of bias.† All included trials re-
ported the method of randomization and the number 
of participants who completed the study. Twenty- 
four trials used power calculations to estimate the 
sample size‡ and 25 trials used intention- to- treat 
principles to analyze the results.§ Twenty- three trials 
had incomplete outcome data because of losing 
more than 10% of the study population.‖ Absence of 
participant and/or investigator blinding was noted in 
30 trials.¶ Individual study- level assessments are pro-
vided in Table 2.
Network Model
The graphical representation of all treatment arms from 
all included trials is shown in Figure 2. The model con-
vergence was achieved with 100 000 iterations at all fol-
low- up time points. Node split analysis showed that the 
estimates of direct, indirect, and network assumptions 
were not significantly different, suggesting the absence 
of large inconsistencies within the network models at all 
follow- up time points (Figure 2A through 2C). The network 
diagnostics using trace and density plots (Figures  S1 
through S3) and node split analysis (Figure 3A through 
3C) showed that the models converged and were valid 
to use at all follow- up time points. The Gelman diagnos-
tics showed a Potential Scale Reduction Factor score 
of 1.000374, 1.000296, and 1.000166 at short- term, 
moderate- term, and long- term follow- up, respectively, 
suggesting the reliability of the network model.
Short- Term Follow- Up
Data were available for the comparison of the follow-
ing treatment combinations at short- term follow- up: 
cilostazol (n=451, 5 arms), HET (n=392, 15 arms), SET 
(n=997, 30 arms), ER (n=333, 9 arms), and SET plus 
ER (n=280, 6 arms) compared with controls (n=1062, 
28 arms). The forest plot suggested that the larg-
est improvement in MWD was achieved by SET plus 
ER (MD, 326.3 m; 95% CrI, 222.6– 430.6). SET (MD, 
186.8 m; 95% CrI, 136.4– 237.6), and HET (MD, 89.4 m; 
95% CrI: 20.9– 157.7) also significantly increased MWD. 
Cilostazol (MD, 71.1 m; 95% CrI, −24.6 to 167.9) and ER 
(MD, 82.5 m; 95% CrI, −2.4 to 168.2) had no significant 
effect on MWD (Figure 4A).
Moderate- Term Follow- Up
Data were available for the comparison of the follow-
ing treatment combinations at moderate- term follow-
 up: HET (n=36, 2 arms), SET (n=499, 12 arms), ER 
(n=367, 7 arms), and SET plus ER (n=197, 4 arms) 
compared with controls (n=228, 7 arms). The forest 
plot suggested that the largest improvement in MWD 
was observed for SET plus ER (MD, 368.5 m; 95% CrI, 
195.3– 546.9) and SET alone (MD, 201.1 m; 95% CrI, 
89.8– 318.3). ER (MD, 84.2 m; 95% CrI, −35.3 to 206.4) 
*References 13, 23–25, 30, 33, 35, 38, 40, 42–44, 48-50, 53–58, 61-63..
†References 6, 20– 22, 26– 29, 31, 32, 34, 36, 37, 39, 41, 45, 47, 60.
‡References 6, 23– 25, 30, 33, 35, 38, 40, 43– 48, 51, 52, 54– 57, 59, 61, 63.
§References 13, 25, 26, 28, 30, 33– 35, 38, 40, 42– 44, 46, 48, 49, 52– 56, 59, 61– 63.
‖ References 6, 21, 24– 26, 28, 31, 32, 34, 35, 37– 40, 43– 45, 47, 48, 54– 56, 61.
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and HET (MD, 99.4 m; 95% CrI, −174.0 to 374.9) had no 
significant effect on MWD (Figure 4B).
Long- Term Follow- Up
Data were available for the comparison of the follow-
ing treatment combinations at long- term follow- up: 
SET (n=124, 4 arms), ER (n=223, 5 arms), and SET plus 
ER (n=104, 3 arms) compared with controls (n=150, 3 
arms). The forest plots suggested that none of the treat-
ments significantly improved MWD as compared with 
controls: SET plus ER (MD, 140.9 m; 95% CrI, −195.4 to 
507.7), ER (MD, 122.7 m; 95% CrI, −64.8 to 347.6), and 
SET (MD, 29.0 m; 95% CrI, −297.1 to 384.6) (Figure 4C).
Ranking Probability
Ranking probability suggested that the SET plus ER 
combination was the best treatment strategy followed 
by SET alone during short- term and moderate- term 
follow- up (Table S2). Initial benefits were abolished at 




A total of 29 trials reported QOL outcomes using differ-
ent generic and disease- specific questionnaires as de-
tailed in Table S3. Generic QOL outcomes were reported 
in 26 trials using the 36- Item Short Form Health Survey 
(SF−36), 12- Item SF,# or the EuroQOL- 5.13,44,63 Disease- 
specific QOL outcomes were reported in 25 trials using 
the Walking Impairment Questionnaire (WIQ),** the 
Vascular QOL Questionnaire (VascuQOL),6,46,52,55,59,62 
the claudication score,50,57 or the Baltimore Activity 
Scale for Intermittent Claudication Questionnaire,29 the 
Intermittent Claudication Questionnaire,51 and peripheral 
artery questionnaire56 respectively. The QOL outcomes 
are reported in Table S3.
Short- Term Follow- Up
Four of 6 arms reported that cilostazol significantly im-
proved QOL as assessed with the SF- 36, VascuQOL, 
or WIQ by comparison with controls.38,46,48 Five of 11 
arms reported that HET significantly improved QOL 
as assessed with the SF- 36 or WIQ compared with 
controls.25,26,28,29 Eleven of 18 arms reported that 
SET significantly improved QOL as assessed with the 
Baltimore Activity Scale for Intermittent Claudication 
Questionnaire, SF- 36, VascuQOL, or WIQ compared 
with controls.25,26,29,34,40,45,52 Seven of 9 arms reported 
that ER significantly improved QOL as assessed with 
the SF- 36, claudication score, VascuQOL, or EuroQOL 
#References 6, 25, 26, 28, 30, 34, 36, 38, 39, 43– 46, 48, 50– 52, 54, 55, 57, 59, 62, 63.
**References 13, 25, 26, 30, 34, 36, 38– 40, 43, 48, 53, 56, 63.
Figure 1. Preferred Reporting Items of Systematic Review and Meta- Analyses (PRISMA) flow 
diagram.
A total of 4021 studies were screened and 46 randomized controlled trials (RCT) were ultimately included. 
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20 (−) (−) (+) (+) (+) (−) High
50 (−) (−) (+) (+) (+) (+) Moderate
35 (+) (+) (+) (+) (−) (+) Moderate
21 (−) (−) (+) (+) (−) (−) High
51 (+) (−) (+) (+) (+) (+) Low
36 (−) (−) (+) (+) (+) (−) High
60 (−) (−) (+) (+) (+) (?) High
37 (−) (−) (+) (+) (−) (−) High
38 (+) (+) (+) (+) (−) (+) Moderate
6 (+) (−) (+) (+) (−) (−) High
22 (−) (−) (+) (+) (+) (−) High
52 (+) (+) (+) (+) (+) (+) Low
62 (−) (+) (+) (+) (+) (−) Moderate
39 (−) (−) (+) (+) (−) (−) High
53 (−) (+) (+) (+) (+) (−) Moderate
26 (−) (+) (+) (+) (−) (−) High
40 (+) (+) (+) (+) (−) (−) Moderate
25 (+) (+) (+) (+) (−) (−) Moderate
61 (+) (+) (+) (+) (−) (−) Moderate
23 (+) (−) (+) (+) (+) (+) Moderate
54 (+) (+) (+) (+) (−) (−) Moderate
41 (−) (−) (+) (+) (+) (−) High
42 (−) (+) (+) (+) (+) (−) Moderate
27 (−) (−) (+) (+) (+) (−) High
43 (+) (+) (+) (+) (−) (−) Moderate
44 (+) (+) (+) (+) (−) (−) Moderate
28 (−) (+) (+) (+) (−) (−) High
63 (+) (+) (+) (+) (+) (−) Moderate
29 (−) (−) (+) (+) (+) (−) High
30 (+) (+) (+) (+) (+) (−) Moderate
55 (+) (+) (+) (+) (−) (−) Moderate
32 (−) (−) (+) (+) (−) (+) High
31 (−) (−) (+) (+) (−) (+) High
56 (+) (+) (+) (+) (−) (+) Moderate
45 (+) (−) (+) (+) (−) (−) High
57 (+) (−) (+) (+) (+) (−) Moderate
46 (+) (+) (+) (+) (+) (+) Low
33 (+) (+) (+) (+) (+) (−) Moderate
58 (−) (−) (+) (+) (+) (+) Moderate
24 (+) (−) (+) (+) (−) (+) Moderate
59 (+) (+) (+) (+) (+) (+) Low
47 (+) (−) (+) (+) (−) (−) High
48 (+) (+) (+) (+) (−) (+) Moderate
13 (−) (+) (+) (+) (+) (+) Moderate
34 (−) (+) (+) (+) (−) (−) High
49 (−) (+) (+) (+) (+) (−) Moderate
Trials with 3 or more negative assessment outcomes were considered to have HIGH risk of bias. Trials with 1 to 2 negative assessment outcomes were 
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by comparison with control.6,28,44,57,59 Four of 4 arms 
reported that the combination of SET and ER signifi-
cantly improved QOL as assessed with the SF- 36, 
VascuQOL, or EuroQOL compared with controls.44,52
Moderate- Term Follow- Up
Seven of 13 arms reported that ER significantly im-
proved QOL as assessed with the SF- 36, VascuQOL, 
claudication score, or peripheral artery questionnaire 
compared with control.6,56,57,62
Two of 4 arms reported that HET significantly im-
proved QOL as assessed with the SF- 36, WIQ, or 
Intermittent Claudication Questionnaire compared 
with control.43,51 Ten of 16 arms reported that SET sig-
nificantly improved QOL assessed by the SF- 36, SF- 
12, WIQ, peripheral artery questionnaire, Intermittent 
Claudication Questionnaire, or VascuQOL compared 
with controls.43,51,52,56,62 Two of 4 arms reported that 
the combination of SET and ER significantly improved 
QOL assessed with the SF- 36 or VascuQOL com-
pared with controls.52
Long- Term Follow- Up
Six out of 11 arms reported significant improvement 
in certain domains of QOL in the ER group using the 
SF- 36, claudication score, VascuQOL, and WIQ ques-
tionnaires.57,62,63 One arm reported that HET did not 
significantly improve QOL as assessed with the WIQ 
questionnaire.43 Two of 7 arms reported that SET sig-
nificantly improved QOL as assessed with the SF- 36 
and VascuQOL questionnaires.54 None of the 4 arms 
testing SET and ER combined reported any significant 
improvement of QOL as assessed with the SF- 36 and 
VascuQOL questionnaires.54,55
Adverse Events
A total of 28 clinical trials reported adverse events as 
defined within the methods section†† (Table  S4). 
None of the trials reported any significant differences 
in SAEs between groups. Twenty- one patients had 
an myocardial infarction as reported in 9 trials.2
4– 26,40,55,56,58,59,63 Thirty patients were reported to 
have had a stroke in 10 trials.‡‡ Events requiring hos-
pital admissions were not reported in any of the in-
cluded trials. Twelve trials reported lower limb 
revascularization procedures performed in 158 pa-
tients during the study follow- up period.§§ Three trials 
reported other vascular procedures performed in 6 
patients.40,54,59 Fifteen patients were reported to have 
required an amputation in 8 trials.6,40,52,53,55,61– 63 
Twenty- one trials reported 149 deaths during the 
follow- up period.‖‖
DISCUSSION
The results of this NMA, suggested that during short- 
term follow- up ER plus SET, SET alone, and HET alone 
all significantly improved MWD in people with inter-
mittent claudication. During moderate- term follow- up 
only ER plus SET and SET alone significantly improved 
MWD. During follow- up of 2  years or more, none of 
these treatments significantly improved MWD. These 
analyses were limited by the small number of partici-
pants included within the available trials meaning the 
††References 6, 13, 24– 26, 33, 35, 38– 40, 43, 44, 47– 59, 61– 63.
‡‡References 6, 13, 25, 26, 35, 40, 47, 54, 55, 63.
§§References 6, 25, 26, 33, 44, 47, 50, 55, 56, 59, 62, 63.
‖ ‖ References 6, 24, 35, 38, 43, 47– 59, 61– 63.
Figure 2. Network plots summarizing all intervention arms in the included trials.
(A) Short- term follow- up, (B) Moderate- term follow- up, (C) Long- term follow- up. The size of the grey lines represent the number 
of trials and the size of the orange circles represent the number of participants in that specific arm. ER indicates endovascular 
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analyses were not adequately powered to identify 
moderate treatment effects.
Cilostazol did not significantly improve MWD during 
short- term follow- up and no trials testing longer- term 
use were identified. The largest benefit was achieved 
for ER plus SET. The findings agree with a prior NMA 
which reported ER plus SET was the most effective 
intervention, although this study did not consider the 
length of follow- up.64 Unlike the prior NMA the current 
report found that ER alone did not significantly improve 
MWD at any time point. This difference is likely reflec-
tive of the separation of outcome data by time of fol-
low- up in the current study. The prior NMA reported 
all outcome data together irrespective of follow- up 
time. The effect of ER alone on MWD during short- 
term follow- up in the current study (MD, 82.5 m; 95% 
CrI, −2.4 to 168.2) was very similar to that reported in 
the prior NMA (MD, 85 m; 95% CrI, 4– 170]). The addi-
tional findings of the current NMA are important be-
cause lack of benefit as early as 2 years after treatment 
may lead to many participants feeling that having the 
treatment is not worthwhile. The findings differ from 
a prior Cochrane review that included a conventional 
MA and reported cilostazol was effective in improving 
MWD.65 This disparity may be because of the much 
smaller number of comparator groups included in the 
Cochrane review, which reported traditional meta- 
analyses. The Cochrane review also included unpub-
lished data and trials reported before 2000, which were 
not included within this meta- analysis. This difference 
in included data likely contributed to the disparate find-
ings of the meta- analyses. NMA includes analyses of 
all included trials including those not compared head 
to head or directly. NMA assumes that it is reliable to 
Figure 3. There were no significant differences in mean difference obtained from direct and indirect evidence.
(A) Short- term follow- up, (B) Moderate- term follow- up, (C) Long- term follow- up. This suggests that very large inconsistencies were 
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compare between participant group included in differ-
ent trials and the consistency analysis and other model 
diagnostics performed in this NMA suggested that the 
indirect comparisons did not introduce any important 
biases or large inconsistencies.
After 2 years follow- up, none of the treatments was 
found to be effective at improving MWD, in line with 
findings from a recent randomized trial.6 These find-
ings emphasize the poor durability of the available 
treatments for intermittent claudication, highlighting the 
need for new therapies. It should be noted, however, 
that the number of patients for whom data were avail-
able at long- term follow- up was limited and the find-
ings may in part reflect the need for further trials testing 
long- term outcomes. Intensive medical management 
is important in people with intermittent claudication in 
order to reduce the risk of major cardiovascular events, 
such as myocardial infarction and stroke. There is now 
good evidence that intensive medical management 
can also reduce the risk of major adverse limb events. 
The recent COMPASS (Cardiovascular Outcomes for 
People Using Anticoagulation Strategies) trial found 
that low- dose rivaroxaban (2.5  mg twice daily) plus 
aspirin significantly lowered the incidence of major ad-
verse limb events as compared with aspirin alone.66,67 
Intensive low- density lipoprotein lowering has also 
been reported to have similar benefits in patients with 
peripheral artery disease.68 Observational studies also 
report a significant reduction in limb loss and mortal-
ity in high- intensity statin users compared with low- 
intensity statin users.69 Greater focus on optimizing 
medical management in people with intermittent clau-
dication may improve QOL and reduce major adverse 
limb events.
Important considerations in selecting treatments 
for intermittent claudication include QOL and adverse 
events. Because of the inconsistent and limited report-
ing of these outcomes, however, it was not possible 
Figure 4. Forest plots of multiple treatment strategies at different follow- up periods.
(A) Short- term follow- up, (B) Moderate- term follow- up, (C) Long- term follow- up. Results are expressed as 
mean difference (95% CrI) in meters. There was significant improvement in maximum walking distance 
at short- and moderate- term follow- up with a combination of SET and ER and SET alone. HET only 
significantly improved maximum walking distance compared with controls at short- term follow- up. No 
treatment was significantly better than controls at long- term follow- up. CrI indicates credible intervals; 
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to meta- analyze these outcomes. Among the included 
trials there was evidence in some trials that all 5 treat-
ment combination were able to improve QOL at short- 
term follow- up, although findings were inconsistent. 
Findings were similar at moderate- term follow- up, ex-
cept that no trials testing cilostazol were identified and 
where available most trials suggested that QOL was 
not improved at long- term follow- up.
Adverse events were infrequently reported in the 
included trials and may not be representative of out-
comes in clinical practice. Little information was re-
ported on perioperative complications following ER, 
drug- related adverse events, and requirement for am-
putation. In addition, because of the inconsistent and 
poor reporting of adverse events, the minimum data 
requirement for meta- analyses focused on serious ad-
verse events and mortality was not met. Large trials are 
needed to examine the effect of exercise on mortality 
and cardiovascular events in people with peripheral 
artery disease. These are important considerations 
when selecting the very different treatment strategies 
available and need more consistent and complete re-
porting in future trials.
A number of limitations of this NMA should be ac-
knowledged, including the limited number of trials, 
particularly testing outcome over the long term and 
examining the effects of cilostazol and HET. Further 
trials examining long- term outcomes, in particular, are 
required to draw reliable conclusions. Limited and in-
consistent information about the medical management 
of participants was reported from the included trials. 
Most authors did not report even the frequency of sta-
tin or antiplatelet medication prescription. Importantly, 
NMA assumes overall similarity between studies, and 
interstudy differences of the included population could 
not be addressed. Variation in medical management 
between the included trials may have contributed to 
the heterogeneous outcomes reported. Furthermore, 
NMA has a number of inherent limitations as it models 
evidence from both direct and indirect comparisons 
and therefore should be interpreted cautiously.70 The 
ranking probability approach shows only the relative 
ranks but not the absolute differences between the dif-
ferent treatment strategies.71 One limitation of the cur-
rent NMA was that trials published before 2000 were 
excluded. This was felt to be required in order for the 
comparison to be contemporary owing to the marked 
evolution of management approaches, particularly ER, 
and trial methods over time. Furthermore, there was 
substantial variation in the HET programs tested.14 
Most SET programs tested involved regular treadmill 
walking. Because the primary outcome was MWD in 
a treadmill test, it is likely this NMA has overestimated 
the benefit of SET owing to an established training to 
the outcome measure phenomenon.72 Furthermore, 
detailed SAEs were not reported in most trials. These 
data are required to appropriately interpret the value of 
each treatment strategy.
CONCLUSIONS
In conclusion, this NMA suggests that ER plus SET 
and SET alone are effective at improving MWD in the 
short and moderate term (ie, under 2 years). None of 
the treatments, however, was effective at improving 
MWD during long- term follow- up. More durable thera-
pies are needed for intermittent claudication.
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((Intermittent claudication[Title/Abstract] OR Peripheral arterial disease[Title/Abstract] OR 
Peripheral arterial disease[Title/Abstract] OR peripheral vascular disease[Title/Abstract] OR 
lower extremity arterial disease[Title/Abstract]) AND (SET[Title/Abstract] OR 
Exercise[Title/Abstract] OR Best medical therapy[Title/Abstract] OR BMT[Title/Abstract] OR 
Percutaneous angioplasty[Title/Abstract] OR PCA[Title/Abstract] OR Surgical 
intervention[Title/Abstract] OR Revascularization[Title/Abstract] OR 
Cilostazol[Title/Abstract])) AND (Maximum walking distance OR MWD OR treadmill OR 
walking distance OR quality of life OR walking capacity OR claudication distance OR 
































Smoking advice, exercise training, nutritional advice, prescribed statins and 
acetylsalicylic acid 







Short Form 36 
(SF-36) and 
VascuQoL 





knee extensions with 
weights, heel raises, 
knee bends and rest 
station to recover. 
Conducted 3 times per week for 12 weeks. The session was supervised by a 
physiotherapist and conducted in the cardiac gym. For the first 6 weeks, 
patients complete one full circuit, followed by on extra station/week, thus 
by 12 weeks patients will complete 2 full circuits. Finally patients perform a 
series of gentle stretching and cooling down exercises. 











24 weeks supervised treadmill exercise, 2x30 minute sessions/week. 
Patients were encouraged to walk at least 30 minutes 3 times/week + walk 1 
hour per day 
ER - 
Iliac revascularisation - self expanding nitinol stent (if initial balloon 
angioplasty not technically successful). Femoral revascularisation - self 
expanding nitinol stent if lumen diameter <50% after initial balloon 
angioplasty. All patients given general recommendations for lifestyle 











TASC II A-C treated with endovascular intervention, TASC II D treated with 
surgical revascularisation. Procedures listed: Aortoiliac endovascular 
procedure, Percutaneous transluminal angioplasty/subintimal angioplasty 










All patients given smoking cessation program + secondary preventative 
pharmacotherapy (single anti-platelet therapy + normal intensity statin 
therapy). All patients also offered Cilostazol treatment. Patients received 
advice including structured exercise therapy (submaximal walking sessions 













Modern nitinol bare metal stents (BMS) were used. Calibrated angiogram 
compared pre- and post-implant minimum lumen diameters. IV heparin 
bolus of 5000 units was administered.  
Control - 
Both groups received daily antiplatelet therapy (75mg aspirin or 75mg 
clopidogrel), lipid lowering and antihypertensive drugs). Patients received a 


















Control group received OMC according to current guidelines - use of 
atherosclerosis risk factor management, cilostazol, home exercise 
counselling  
SET Treadmill walking 
SET patients received OMC + SET. Consisted of treadmill walking for up to 78 
scheduled exercise sessions that were 1 hour long, 3 days a week for 6 
months. Patients received quarterly contact by research coordinators during 
supervised phase - then participated in a telephone-based maintenance 
program (7-12 months) to promote exercise adherence.  
ER - 
EVR patients received OMC + stent revascularisation of hemodynamically 









Stair climbing, heel 
raises and treadmill 
walking 
Percutaneous transluminal angioplasty  
SET 
Stair climbing, heel 
raises and treadmill 
walking 
SET consisted of 30 minutes of continuous exercise to a maximum pain 
threshold using walking circuit interspersed with 7 lower limb training 
stations (eg. stair climbing, heel raises, treadmill walking) supervised by 
physiotherapists or nursing staff. All participants underwent OMC which 
involved: assessment of BP measure, dyslipidaemia, serum glucose and anti-




















All patients were advised to give up smoking. Control patients received no 
other specific advice or treatment apart from the general advice given to the 
two treatment groups  
SET Treadmill walking 
SET patients were referred to trained physiotherapists - 30 minute sessions 
of specific walking training per week during the initial 6 months with 10-12 
patients participating in each training class as described. After 6 months 2 
sessions per week were offered 
ER - 
EVR patients were referred for standard angiography. Based on these 






Short Form 36 
(SF-36) [26], as 







- Percutaneous transluminal angioplasty 
SET+ER 
Treadmill walking 
and high intensity 
exercises 
SET two days per week for 12 weeks + one home based exercise session per 
week. After hospital based SET, participants conducted home based exercise 
sessions every week for an additional 12 weeks. Each session lasted 60 
minutes (consisted of warm-up exercises, 3 high intensity intervals, two 











Endovascular revascularisation was performed by an interventional 
radiologist. For iliac revascularisation: initial balloon angioplasty, if that failed 
then self-expanding nitinol stent was used. For femoral revascularisation: 
self-expanding nitinol stent was chosen based on angiography.  
SET 
Treadmill walking 
without a graded 
incline and variations 
in speed 
SET performed over 24 weeks on a walking treadmill - 30 minutes per 
session, twice weekly supervised by a vascular technologist. Treadmill 
exercise was initiated at a workload of 3.5km/h without a graded incline and 
decreased to 1km/h when perceived maximum claudication pain occurred, 
and increased after a few minutes after the pain subsided.  
Crowther 
2008 














increase in intensity 
and duration 
Exercise program initial consisted of treadmill walking 3 days per week for 
25 minutes at 3.2 km/hr. Participants were required to walk until pain level 
was perceived as 3 or 4 on the CPS. Exercise intensity (treadmill grade and 
walking speed) and duration (25 to 40 minutes) was progressively increased. 
















All patients were given best medical treatment (antiplatelet therapy, 
antihypertensive therapy, cholesterol lowering agents and diabetic control. 
Each patient received verbal and written exercise advice - recommended a 
program of walking at least 3 times a week to near maximal pain for at least 
half an hour per session. Additional leg exercises were to be performed at 




climbing, low step 
climbing, high step 
climbing, tip toe 
walking, standing on 
tip toe from flat, 




A 45 minute class was conducted under physiotherapy and medical 
supervision in a standard hospital gym. Commenced with a 5-10 minute talk 
on benefits of walking. Followed by half an hour of exercise consisting of a 
walking circuit and performing seven 2 minute exercise stations for lower 
limb strengthening. Stair climbing, low step climbing, high step climbing, tip 
toe walking, standing on tip toe from flat, standing on tip toe from ankle 
dorsi-flexion and power-jogger walking. Each 2 minute station was 























Supervised 6 months progressive exercise program followed by supervised, 
12-month maintenance exercise program. The progressive program 
consisted of intermittent treadmill walking to near maximal claudication pain 
3 days per week at a walking speed of approximately 2 mph. Walking 
duration began at 15 minutes for the first month of the program, and 
progressively increased by 5 minutes per month until a total of 40 minutes 
of walking was accomplished by the sixth month of rehabilitation. Walking 
intensity began at 50% of the maximal work load achieved during a maximal 
effort treadmill test, and progressively increased on an individual basis 
throughout the program to 80% by the sixth month of rehabilitation. Five 
minutes of cycling on a stationary bicycle ergometer served as both warm-
up and cool-down exercise during each session. The final 12 months of the 
exercise program was considered the maintenance phase in which the 
frequency of exercise sessions was reduced to 2 days per week. Walking 
duration and intensity were maintained at 40 minutes and 80% of the 









Subjects performed three 60-minutes supervised exercise training sessions 
each week for a period of 3 months. Subjects walk on a treadmill at an initial 
speed of 2.0 mph to a mild to moderate pain level, stop and rest until the 
claudication pain has completely abated, and then resume walking. This 
pattern was repeated for a total of 60 minutes. If subjects can walk longer 
than 8 minutes without rest, the treadmill walking becomes more 
challenging via grade and speed increases in subsequent training sessions.  










Patients were randomized to one of five study arms: placebo, K-134 at a dose 
of 25, 50, or 100 mg, or cilostazol at 100 mg, each twice daily. 























All participants viewed a 7-minutes educational video about PAD and its 
clinical leg symptoms, life-threatening consequences of PAD (heart attack 
and stroke), other adverse outcomes (walking disability), and strategies for 
disease and risk factor management (smoking cessation, weight control, 
aerobic activity). After the video, each participant met face-to-face with the 
research coordinator. Participants were encouraged to ask questions about 
the video material. The coordinator queried participants regarding self-
management behaviors (i.e., glucose monitoring, blood pressure monitoring) 
and gave them a calendar in which to document their daily glucose results, 
weekly blood pressures, and any routine lipid results provided by their 
primary care physician. 
HET - 
Intervention group subjects participated in a home-based walking program 
with three components: 1) A one-on-one interaction with the research 
coordinator at baseline; 2) Walking training and weekly group walking classes 
with an instructor; 3) Bi-weekly telephone calls for 6 months. Participants 
were then encouraged to walk 1 day per week with the study exercise 
instructor and other participants, as available, and to continue walking on 
their own at least 3 days per week for a minimum of 4 days of walking each 
week. Participants were advised to walk 50 minutes total for each session, 

















increase in intensity 
and duration 
The exercise program initially consisted of intermittent supervised treadmill 
walking 3 days per week for a total time of 25 minutes at 3.2 km/hr (0.88 
m/s). Participants were required to walk until the pain level was perceived 
as being 3 or 4 on the CPS. Exercise intensity (via treadmill grade and walking 
speed) and duration (25 minutes up to a maximum of 40 minutes) were 
progressively increased once the participant could walk continuously for 25 
minutes at a level below 3 on the CPS pain scale. This exercise progression 
strategy was continued over the 6-month period. 
Control - 
Standard medical treatment as outlined in the Trans-Atlantic Inter-Society 































ER performed by experienced interventional radiologist or vascular surgeon. 
For iliac and femoral revascularizations, a stent was used only if the initial 
balloon angioplasty was not successful (selective stenting). In addition, 
within 2 to 4 weeks after the procedure, patients were enrolled in the 
supervised exercise program described above. 
SET Treadmill walking 
Exercise program consisted of treadmill walking to near maximum 
claudication pain. Physiotherapists were advised to start with a frequency of 
2 to 3 sessions every week and approximately 30 to 45 minutes per session 
during the first 3 months. After this phase, the frequency was reduced to at 
least 1 session per week between months 3 and 6 and then to a frequency 










Form 36 (MOS 
SF-36) 
Treadmill walking 
The exercise rehabilitation program consisted of 6 months of supervised, 
intermittent treadmill walking to near maximal claudication pain 3 days per 
week as previously described. 
Control - 
The control group did not receive any recommendations regarding exercise 














increase in duration 
Exercise sessions in our supervised exercise program were performed while 
wearing a step activity monitor as previously described. Briefly, the 
supervised program consisted of 3 months of intermittent treadmill walking 
to mild-to-moderate claudication pain 3 days per week at a speed of 2 mph 
and at a grade equal to 40% of the highest work load achieved during the 
baseline maximal treadmill test. Sessions progressively increased during the 









This program consisted of 3 months of intermittent walking to mild-to-
moderate claudication pain 3 days per week at a self-selected pace, in which 
exercise duration was progressively increased from 20 to 45 minutes per 
session. Patients wore the step activity monitor during each exercise session 
and returned the monitor and a logbook to the research staff at the end of 
week 1, 4, 8, and 12. During these brief 15-minute meetings, monitor data 
were downloaded, results were reviewed, and feedback was provided for the 
upcoming month of training. 
Control - 
Attention-Control, light resistance program. Light resistance training was 
performed 3 times per week, without any walking exercise, using a Pro-Form 
Fusion 6.0 LX weight system. On entry, the resistance that caused fatigue in 
various muscle groups after 15 repetitions (15-rep maximum) was 
established, and was reassessed each month. The resistance training phase 
consisted of performing upper extremity exercises that included the bench 
press, military press, butterfly, biceps curl, triceps press-down, and lat 
pulldown. Lower extremity exercises included the leg press, leg curl, and leg 
extension. One set of 15 repetitions was performed for each exercise. If the 
resistance from the exercise machine could not be lifted, resistance bands 











increase in intensity 
and duration 
This program consisted of 6 months of supervised intermittent treadmill 
walking to near-maximal claudication pain 3 days per week. Walking 
duration and intensity of the sessions were progressively increased during 
the program. Walking duration began at 15 minutes for the first month of 
the program and increased by 5 minutes per month until 40 minutes of 
walking was accomplished by the sixth month of rehabilitation. Walking 
intensity began at an initial grade of 50% of the final workload attained 
during the baseline graded treadmill test and was increased by 10% every 6 
weeks up to 80% during the final 6 weeks of the exercise program. During 
each exercise session, patients walked at approximately 2mph until their 
claudication pain reached a level of 3 on a 0 to 4 pain scale. 
Control - 
This group were encouraged to walk more on their own but did not receive 
























Home-based exercise program was designed to be as similar to the 
supervised exercise program as possible, and consisted of 12 weeks of 
intermittent walking to near maximal claudication pain three days per week 
at a self-selected pace. Walking duration began at 20 minutes for the first 
two weeks, and progressively increased five minutes bi-weekly until a total 
of 45 minutes of walking was accomplished during the final two weeks of the 
program. These exercise durations were five minutes longer throughout the 
program than in the supervised program in an attempt to better match the 
programs on total volume of exercise determined by multiplying the 




increase in intensity 
and duration 
This standardized program consisted of three months of supervised 
intermittent treadmill walking, three days per week at a speed of 
approximately two mph. Walking duration began at 15 minutes for the first 
two weeks of the program, and progressively increased by 5 minutes 
biweekly until a total of 40 minutes of walking was accomplished during the 
final two weeks of the program. Because we have previously shown that 
changes in COT and MWT are similar for patients who train at a relatively 
high exercise intensity (80% of peak work load) and patients who train at a 
lower intensity (40% of peak work load) for longer duration. 
Control - 
This group were encouraged to walk more on their own but they did not 



















Gym exercise and 
treadmill walking 
with varied intensity 
This sequence involved a shuttle walk at moderate to hard pace; paired toe 
raising to heel raising, with chair support for balance; continuous sitting and 
standing from chair; spot marching with high knees, swinging arms; arm 
exercises from the upright sitting position (side arm raising, alternate arm 
vertical pushing, and side bent-arm lift); shuttle walk at moderate to hard 
pace; knee bends with chair support for balance; alternate heel raising 
(left/right) with chair support for balance; step-ups on bench or stairs; and 
arm exercises from the upright sitting position (straight side arm small 
backward circling, double arm vertical pushing, and side bent-arm lift, 
alternating arms. Twice weekly 1 hour exercise sessions - subjects underwent 
3 minutes of activity at multiple stations followed by 2 minutes of rest. On 
days when not attending the supervised sessions, subjects were asked to 
perform the exercise program unsupervised at home. Training logs were kept 
to detail the number of repetitions performed and the maximal heart rate at 









The supervised exercise comprised a 3-month, twice weekly, 1-hour 
physiotherapist-led exercise program. In addition to the supervised sessions, 
subjects were provided with a videotape of the exercise program and 
encouraged to undertake the exercises at home and complete an exercise 




Cilostazol was prescribed at a dose of 100 mg twice daily. If side effects were 
encountered (most commonly headache and diarrhoea), the dosing regimen 




Treadmill exercise Programs were as followed in both SET and Cilostazol groups 












Patients in the supervised group visited the hospital twice weekly for a period 
of 12 weeks. During the session patients were encouraged to walk on a 
treadmill (3.2 km/h) and 75% of the initial grade achieved during the exercise 
test) until they reached stage three or four on the PAD pain scale. Repeated 









The patients in the control group were given normal treatment. These 



















All patients received the following: Current smokers were advised to stop 
smoking, antiplatelet therapy, preferably 75mg aspirin once daily, was 
commenced if the patient was not already on it and lipid-lowering agents 
(statins) were prescribed and titrated to reduce LDL serum levels below 2.5–
3 mmol/L, if necessary. Patients allocated to unsupervised exercise (control 
group) were advised to exercise daily by walking as much as possible to near 




increase in intensity 
and duration 
Patients attended the physiotherapy department for exercise therapy three 
times per week for the first 6 months. Compliance was assessed with 
logbooks. Supervision was provided on an individual or group basis and each 
session lasted for about 60 minutes. A session consisted of 5 minutes warm 
up activities, 50 minutes of intermittent exercise and ended with 5 minutes 
of cool-down activities. Walking treadmill exercise was started at a low 
treadmill workload of 2 mph, 0% grade. Patients walked until claudication 
pain become moderately severe, at which time they step off the treadmill 
and rest until claudication pain subsides. After the patient had walked 8–10 
minutes at the initial workload, either the grade was increased by 1–2%, or 






















All patients received cardiovascular risk factor modification, including 
therapy with a platelet inhibitor and a statin and treatment of hypertension 
or diabetes or both as required. All patients who smoked were repeatedly 
advised to quit smoking and were offered a smoking cessation program. All 
patients were advised concerning lifestyle changes (eg, physical activity, 
weight, diet) according to the Dutch standard for cardiovascular risk 
management. The choice for a primary PVI for the individual patient was 
based on the results of imaging with duplex ultrasound or magnetic 
resonance angiography or both as discussed in a multidisciplinary meeting of 
interventional radiologists and vascular surgeons. Mainly iliac lesions 
generally were treated with a PVI, and depending on lesion classification, 
femoropopliteal lesions also were treated. Not all lesions were necessarily 
treated. All PVIs were performed by an experienced interventional 
radiologist and consisted of iliac angioplasty with selective stent placement 
for iliac stenoses, angioplasty with primary stent placement for superficial 
femoral artery stenoses, or recanalization with primary stent placement for 
iliac and femoral occlusions. 
SET+ER 
Treadmill walking, , 
Cycle ergometer, 
Indoor walking 
space, Small group 
exercise room 
Patients in the PVI SET group, the SET program was scheduled to start within 
3 weeks after the PVI. The SET program was performed in a community-
based setting, meaning that patients followed exercise therapy by a trained 
physiotherapist in proximity to their homes. Organization and results of 
community-based SET have been described previously. SET was 
administered according to the guidelines of the Royal Dutch Society for 
Physiotherapy. The main goal of SET is to increase a patient’s walking 
distance by interval training with short (3–5 minutes) walking intervals up to 
submaximal pain (distraction not possible). Secondary goals are increasing 
endurance and strength and improving walking patterns. Patients generally 
started with a frequency of two to three sessions of 30 minutes a week. 
Frequency of the sessions was phased down according to the patient’s 

















Form 36 (MOS 
SF-36) 
- 
The program included two 10-minute sessions/day (6 days/week) of 
intermittent walking (1-minute work and 1-minute rest while seated) at a 
prescribed speed converted into a walking cadence and followed at home 
using a metronome. A semipersonalized training program was proposed 
according to the patient’s baseline exercise capacity (ICD less than or greater 
than 50 metres). The walking sessions were preferably performed indoors at 
home (eg., in a hallway or a heated garage) to avoid the influence of weather 
or on a treadmill. 
ER - 
Open surgery or endovascular revascularization or both were planned. The 
team included highly experienced vascular surgeons and interventional 
radiologists. For each patient, the team performed the option that was most 
likely to yield the best hemodynamic improvement. After intervention, the 
patients received general recommendations regarding lifestyle changes and 












recovered on an 
exercise bike with no 
resistance 
Interventions consisted of 36 training sessions, two or three times per week, 
according to the patient’s preferences. If patients could not attend 
prescheduled sessions, they were offered a new rescheduled session in the 
same week. A single training session lasted around 60 minutes and consisted 
of walking on a treadmill, followed by active recovery on an exercise bike 
with no resistance. 
Control - 
The control group was advised to continue with secondary preventive 

















increase in duration 
Supervised exercise rehabilitation program that was designed to elicit 
increases in COT and PWT as previously described. This standardized 
program consisted of 3 months of supervised treadmill walking sessions 3 
days per week. Walking duration began at 15 minutes for the first 2 weeks 
of the program and progressively increased by 5 minutes bi-weekly until a 
total of 40 minutes of walking was accomplished during the final 2 weeks of 
the program. Patients walked at a grade equal to 40% of the final workload 
from the baseline maximal treadmill test to the point of near-maximal 









Patients randomized to this group (n = 7) participated in supervised light 
resistance training over the 3-month study period. Light resistance training 
was performed three times per week, without any walking exercise, using a 
Pro-Form Fusion 6.0 LX weight system. On entry, the resistance that caused 
fatigue in various muscle groups after 15 repetitions (15-rep maximum) was 
established and was reassessed each month. The resistance training phase 
consisted of performing upper extremity exercises that included the bench 
press, military press, butterfly, biceps curl, triceps press down, and lat pull-
down. Lower extremity exercises included the leg press, leg curl, and leg 
extension. One set of 15 repetitions was performed for each exercise. If the 
resistance from the exercise machine could not be lifted, resistance bands 
were used instead. 
HET - 
Home-based exercise rehabilitation program that was designed to be as 
similar to the supervised Exercise program as possible and consisted of 12 
weeks of intermittent walking to near-maximal claudication pain 3 days per 
week at a self-selected pace. Walking duration began at 20 minutes for the 
first 2 weeks and progressively increased 5 minutes bi-weekly until a total of 













Patients assigned to the control group received verbal advice to exercise but 
no other formal training. 
HET - 
Patients in the intervention group received in-hospital exercise training on a 
treadmill for an initial 2 weeks (3 days/week). Patients then completed 12 
weeks of community-based walking exercise training. Patients instructed to 
walk/rest on treadmill for 35 minutes progressing to 50 minutes as tolerated. 
Intensity enough to induce moderate leg pain in 3-5 minutes for patients 







NA Treadmill walking 
Patients in the treatment group participated in 12 weeks of supervised 
treadmill training. The exercise training sessions were conducted three times 
a week on a treadmill during the morning hours. Treadmill speed was set at 
3.2 km/hr and at an inclination on 12 degrees. The session consisted of 








free walking distance. The goal of such a workload was not to produce a 
claudication pain. 













Patients in the training group participated in a 12-week supervised treadmill 
training programme. The sessions were conducted in the morning, three 
times per week and consisted of repetitive walking exercise with 3-minutes 
resting intervals. During each session, after 5 minutes of warm-up activities 
(free cycling on a stationary cycle ergometer), subjects walked on the 
treadmill at a speed of 3.2 km/h and a grade that induced claudication pain 
within approximately 3 to 5 min. Walking was continued until onset of 
claudication pain (level 2 on pain scale). The main goal of this protocol was 
to approach but not continue walking beyond the claudication pain. Patients 
stopped exercise when the pain level 2 was reached. Both the duration and 
intensity of sessions were progressively increased during the programme. 
Control - 
Control group were advised not to change their usual level of activity. All 
study participants were encouraged to stop smoking. Their diet was neither 

















Quality of Life 
(VascuQoL) 
- Cilostazol 100 mg twice daily 









with diary to 
complete 
The SET group were given an exercise diary to complete and instructed to 









HET group were given an exercise diary to complete and instructed to 
undertake three 30 minutes walking sessions per week at a RPE of 12 - 14. 
This group was also contacted weekly by telephone and given support and 
encouragement in adhering to the protocol.  
Control - 
The control group were given verbal information regarding the safety and 
efficacy of walking exercise but no specific instructions were given regarding 









Patients underwent a standardized training program twice a week for six 
months. SET was based upon the current guidelines for patients with 
intermittent claudication and was guided by physiotherapists. After a warm 
up period of 5–10 min, the initial duration included 35 minutes of 
intermittent walking which was increased by 5 minutes each session until 50 
minutes of intermittent walking was accomplished. The workload of exercise 
training was set to a walking speed that elicited claudication symptoms 
within 3–5min. Patients were trained at this workload until they achieved 
moderate claudication followed by a brief resting period to allow symptoms 
to resolve 







Circuit format with 
no treadmill walking 
Supervised exercise program comprised 5 different exercises in a circuit 
format. Patients were advised to rest when symptoms of claudication 
became intolerable and to recommence exercise when the pain subsided. 
After 8 minutes, the patients moved on to the next exercise. Two 1 hour 
classes were run each week, each with a maximum exercise time of 40 
minutes with 10 minutes warm-up and cool down periods. The exercises 
were mainly based on calf muscle and could be continued at home without 
the need for specialized equipment. Treadmill exercises were not included 
to avoid the potential bias between the groups. 




































The intervention was modelled on the structured education self-


















Patients in the exercise group performed the treadmill exercise three times 
each week until 12 weeks. Exercise training began with 5 minutes of warm 
up and ended with 5 minutes of cool down. During exercise, patients’ heart 
rate and 12-lead electrocardiogram were continuously monitored to detect 
any exercise-induced dysrhythmias. Arm blood pressure values and 
claudication pain scores were collected every 5 minutes Exercise intensity 
started from 2 mph, 0% grade, with 1% grade increase every 10 minutes if 
patients reported a claudication pain score below 2. Patients were 
encouraged to exercise up to 30 minutes with their claudication pain scores 
between 2 and 3 (pain levels between mild and moderate). 







NA Cycling exercise 
SET twice a week for 24 weeks. For each of the supervised training sessions, 
patients exercised in cycles of 2 minutes exercise at a crank rate of 50 
rev/min, followed by 2 minutes rest, for a total exercise time of 20 minutes 
in a 40-minute session. For the upper limb aerobic exercise training, the arm-
crank ergometer was placed on a table in front of the seated patient with the 








SET Cycling exercise 
For lower limb aerobic exercise training, the seat height was adjusted to 
allow slight knee flexion at bottom dead centre. Up to eight patients 
exercised together in the same session. 
Control - 
Patients in the control group were given lifestyle advice, including 













Patients wore the Fitbit device for 2 weeks, and were told to continue normal 
activities without purposely increasing or decreasing exercise. 














The program of supervised walk training was carried out for three months 
(36 training sessions), three times a week from 30 (first week) up to 50 min. 
Each training began with a short warm-up (5–10 min) which consisted of 
flexibility exercises for upper and lower extremities and spine. Training was 
ended with stretching and breathing exercises (3–5 min). Treadmill training 
was conducted on a treadmill HX-100 with the constant workload protocol 
based on TASC II guidelines. Speed and slope were constant, amounted to 
3.2 km/h (2.0 mph) and 12% grade. Patients walked up to the reach of 
submaximal level of pain (ACSM – level 4) and next rested in standing 
position when the level of pain decreased to 1 (no pain) but no longer than 






Nordic pole walking 
NPW was performed by a qualified physiotherapist using the NW technique 
according to the guidelines of the International Nordic Walking Federation 
(INWA) with the KV+ poles. The pole length was adopted for each subject 
based on body height (0.7 × height). Patients trained under the same 
conditions as in TT. During the rest period, patients monitored HR 




















Nordic pole walking 
Before Nordic walking sessions, all NWG patients received individual training 
for 30 minutes on the handling of poles and the technique of Nordic walking, 





Walking on flat 
surface 
 Walking sessions for both groups started after a 10-minutes warm-up to 
stimulate and effectively prepare the cardiorespiratory and muscular system 
for the effort. Then, each patient performed a 45-minutes session of walking 









The HEP group was given written instructions to walk at their normal pace 




Patients in the NPW group were given a pair of LEKI Nordic walking poles 
adjusted for height (height × 0.7) and asked to walk using the poles for at 
least 30 minutes three times per week. 
ACSM – The American College of Sports Medicine; BMS – Bare metal stent; BP – Blood pressure; COT – Claudication onset time; CPS – Composite 
pain scale; d – Day; ER – Endovascular revascularization; HET – Home exercise therapy; HR – Heart rate; ICD – Intermittent claudication distance; 
IC – Intermittent claudication; INWA – International Nordic walking federation; km/h – Kilometer/hour; mg – Milligram; m/s – meters/second; 
mph – Miles per hour; MWD – Maximum walking distance; MWT – Maximum walking time; NR – Not reported; NPW – Nordic pole walking; OMC 
– Optimal Medical Care; PAD – Peripheral artery disease; PTA – Percutaneous transluminal angioplasty; PVI – Percutaneous vascular intervention; 
PWT – Peak walking time; RPE – Ratings of perceived exertion; SET – Supervised exercise therapy; TASC – Transatlantic Inter-Society Consensus; 
















Table S2. Ranking probability percentage of each treatment arms. 
 
Ranking probability (%) - Short term follow-up 
  Rank1 Rank2 Rank3 Rank4 Rank5 Rank6 
Control 0 0 0 0.09 6.62 93.28 
HET 0 0.28 13.93 47.83 37.23 0.73 
ER 0.02 13.79 54.79 22.43 8.75 0.2 
Cilostazol 0.03 3.18 14.83 28.79 47.37 5.78 
SET 0.25 82.45 16.42 0.85 0.01 0 
SET_ER 99.68 0.29 0.02 0 0 0 
       
Ranking probability (%) - Moderate term follow-up  
  Rank1 Rank2 Rank3 Rank4 Rank5  
Control 0 0.03 1.86 18.48 79.63  
ER 0.03 1.62 43.96 50.54 3.83  
HET 1.1 10.07 41.6 30.68 16.53  
SET 0.95 86.53 12.24 0.26 0  
SET_ER 97.9 1.73 0.33 0.03 0  
       
Ranking probability (%) - Long term follow-up   
 Rank1 Rank2 Rank3 Rank4   
Control 2.97 9.65 22.6 64.72   
ER 41.56 41.93 15.51 1   
SET 3.01 16.59 49.59 30.49   

























Significant improvements were seen 
in physical functioning and reported 
health transition. 
Bodily pain and reported 
health transition were 
significantly improved 
Only reported health transition 
domain was significantly improved 
ER 
Only physical functioning domain 
was significantly improved. 
Remaining domains did not change 
Bodily pain and reported 
health transition were 
significantly improved 
Only reported health transition 






None of the domains significantly 
improved 
Only severity of pain was 
significantly improved 
Only pain during activity was 
significantly improved 
ER 
Pain during activity and severity of 
pain significantly improved. Other 
domains including everyday life, pain 
related to sleep, social life, specific 
fears related to illness and 
psychological well-being did not 
change 
Only pain during activity was 
significantly improved 







None of the domains significantly 
improved 
SET NA NA 
None of the domains significantly 
improved 
SET+ER NA NA 








None of the domains significantly 
improved 
SET NA NA 
None of the domains significantly 
improved 
SET+ER NA NA 














Physical function, bodily pain 
and general health 
significantly improved 
General health domain significantly 
decreased 
ER NA 
Physical function, role physical 
and bodily pain significantly 
improved 
Physical functioning, role physical 








VascuQoL and rating score 
significantly improved 
Only VascuQoL score significantly 
improved 
ER NA 
VascuQoL and rating score 
significantly improved 





Physical functioning and bodily pain 
significantly improved compared to 
baseline and control group 
Domains including physical 
functioning, role physical and 
bodily pain significantly 
improved 
None of the domains significantly 
improved 
Control 
None of the domains significantly 
improved 
Domains including physical 
functioning, role physical and 
bodily pain significantly 
improved 







Domains including activities, 
symptoms, and emotional were 
significantly increased 
All domains significantly 
improved 
None of the domains significantly 
improved 
Control 
None of the domains significantly 
improved 
All domains significantly 
improved 







Domains including physical 
functioning, bodily pain, vitality 
and physical component summary 
were significantly improved 
Control NA NA 




NA NA EQ5D did not significantly improve 
Control NA NA EQ5D did not significantly improve 

















No significant improvement in 
SF-12 physical score 
NA 
SET NA 
SF-12 physical score was 
significantly improved 
compared to control but no 
difference within intragroup 
NA 
ER NA 
SF-12 physical score was 
significantly improved 
compared to control but no 







No significant improvement in 




Pain severity and walking 
distance were significantly 
improved compared to control 




Pain severity and walking 
distance were significantly 
improved compared to control 








No significant improvement in 
physical limitation, symptoms, 
QoL and summary 
NA 
SET NA 
Only PAQ summary was 
significantly improved 











Physical limitation, symptoms, 
QoL and summary improved 
compared to baseline and 
control. Physical limitation, 
QoL and summary were 
significantly improved 






NA NA None of the domains significantly 





NA NA Physical score domains significantly 
improved compared to SET, but no 
significance reported comparing 
with baseline 




NA NA NA 
SET NA NA NA 




NA Physical function, bodily pain 
and vitality were significantly 
different between the groups, 
but not reported against 
baseline. 
NA 






NA Daily life domain showed a 
trend towards improvement 
but not statistically different. 
Other domains did not 
change. 
NA 





None of the domains significantly 
improved 




None of the domains significantly 
improved 








None of the domains significantly 
improved 











None of the domains significantly 
improved 







NA NA NA 





NA Physical functioning was 
significantly improved in SET 
compared to HET group 
NA 
SET NA NA 
HET Disease 
specific 









Scores did not change between pre 
and post intervention 
Scores did not change 




Scores did not change between pre 
and post intervention 
Scores did not change 






NA NA NA 
Control NA NA NA 
Brass 2012 
Cilostaz
ol NA NA 
NA NA NA 





Only mental health domain 
significantly improved in HET 
compared to control group 
NA NA 





Walking speed domain significantly 
improved in HET compared to 
control group 
NA NA 





NA NA NA 





































Physical functioning, bodily pain, 
physical role functioning score and 
general health perceptions were 
significantly improved 
Physical functioning, bodily 
pain, physical role functioning 
score and general health 




Physical functioning, bodily pain, 
physical role functioning score and 
general health perceptions were 
significantly improved 
Physical functioning, bodily 
pain, physical role functioning 
score and general health 








VascuQoL and rating score 
significantly improved 




VascuQoL and rating score 
significantly improved 









None of the domains significantly 
improved 




None of the domains significantly 
improved 







None of the domains significantly 
improved 




None of the domains significantly 
improved 









Physical function significantly 
increased compared to baseline 
NA NA 
HET 
Physical function significantly 

















Walking economy and fractional 
utilization increased significantly 




Walking economy and fractional 
utilization increased significantly 









































Fractional utilization, walking 
distance, speed and stair climbing 
scores significantly increased 
NA NA 
SET 
Walking economy, fractional 
utilization, walking distance, speed 




Fractional utilization significantly 
improved 
NA NA 










ER NA NA NA 





NA NA NA 
Cilostaz
ol 




NA NA NA 





NA NA NA 





None of the domains significantly 
improved 
Only mental health sub-
domain significantly improved 
NA 
SET 
None of the domains significantly 
improved 
Only mental health sub-






None of the domains significantly 
improved 
None of the domains 
significantly improved 
None of the domains significantly 
improved 
SET 
None of the domains significantly 
improved 
None of the domains 
significantly improved 








Domains including mental health, 
vitality and mental summary score 
were significantly improved in 
SET+ER as compared to ER only 
NA NA 






Both total score and general health 
were similar in both treatment 
strategies 
NA NA 






physical component summary, 
bodily pain, emotional role, general 
health, mental component summary, 
mental health, physical functioning, 
physical role, social functioning and 










physical component summary, 
bodily pain, emotional role, physical 
functioning, physical role and vitality 






Physical functioning, bodily pain and 














Change in BASIC score significantly 
improved  
NA NA 
HET NA NA 
Control 
Scores did not change between pre 
















Distance, speed and combined 
percentage significantly improved 










NA NA NA 




NA NA NA 






Physical function and physical 
component summary were 
significantly improved. Physical 
function was significantly improved 


















Pain domain significantly improved NA NA 
Control 







NA NA NA 
HET NA NA NA 





NA NA NA 





NA NA NA 






Significant improvement in physical 
function, and a trend towards 
improvement in bodily pain, role-
physical and general health 
perception compared to placebo 
NA NA 





Walking distance score improved but 
significance not reported 
NA NA 






Superior improvement in WIQ 
speed, distance and stair-climbing 
scores compared to control, but 
significance not reported 
NA NA 
HET NA NA 
Control 
Generic EQ5D 



















Significant improvement was seen in 
physical function, role 
limitations/physical, bodily pain, 
general health and vitality as 
compared to baseline and control 
NA NA 
Control 







Significant improvement was seen in 
WIQ distance, speed and stairs 
walking compared to baseline. Only 











NA NA NA 
SET NA NA NA 





NA NA NA 





ll) NA NA 
NA NA NA 
SET 
(NPW) 










NA NA NA 












NA NA NA 
* Data compares intergroup only. Intragroup comparing against baseline not available. 
BASIC-Q – Baltimore Activity Scale for Intermittent Claudication questionnaire; CLAU-S – Claudication scale; ICQ – Intermittent Claudication 
Questionnaire; ER – Endovascular revascularization; EQ5D – EuroQol-5D; HET – Home exercise therapy; MOS-SF36 – Medical Outcomes Study; 
NA – Not available; PAQ – Peripheral artery questionnaire; QoL – Quality of life; SET – Supervised exercise therapy; SF – Short Form; NPW – 



















Table S4. Adverse events reported in all included trials. 
 

















Nylande 2007 Control 28 24 NR NR NR NR NR NR 0 
Nylande 2007 ER 28 24 NR NR NR NR NR NR 1 
Mazari 2017 ER 60 60 4 2 NR 14 NR 1 14 
Mazari 2017 SET 60 60 2 1 NR 10 NR 0 13 
Mazari 2017 SET_ER 58 60 3 5 NR 6 NR 0 12 
Fakhry, 2013 SET 75 84 NR NR NR 32 NR 2 17 
Fakhry, 2013 ER 75 84 NR NR NR 17 NR 3 15 
Djerf 2020 ER 79 60 NR 2 NR 22 NR 0 13 
Djerf 2020 Control 79 60 NR 2 NR 20 NR 1 7 
Lindgren 2018 ER 45 24 3 2 NR 10 NR 1 1 
Lindgren 2018 Control 47 24 2 0 NR 7 NR 0 1 
Murphy 2015 Control 22 18 1 NR NR 0 NR NR 0 
Murphy 2015 SET 43 18 0 NR NR 0 NR NR 1 
Murphy 2015 ER 46 18 0 NR NR 1 NR NR 0 
Gelin 2001^ Control 89 12 NR NR NR NR NR 2 4 
Gelin 2001^ SET 88 12 NR NR NR NR NR 0 5 
Gelin 2001^ ER 87 12 NR NR NR NR NR 1 5 
Bo 2013 ER 21 12 NR NR NR 
6* 
NR NR 0 
Bo 2013 SET_ER 29 12 NR NR NR NR NR 1 
Spronk 2009 ER 75 12 1 NR NR 2 0 NR 5 
Spronk 2009 SET 75 12 0 NR NR 4 3 NR 3 
Crowther 2008 Control 11 12 NR NR NR NR NR NR NR 
Crowther 2008 SET 10 12 NR NR NR NR NR NR NR 








Gardner 2002 SET 17 18 NR NR NR NR NR 1 1 
Baker 2017 SET 29 3 NR NR NR NR NR NR NR 
Baker 2017 Control 35 3 NR NR NR NR NR NR NR 
Brass 2012 Cilostazol 89 6.5 NR 1 NR NR NR NR 1 
Brass 2012 Control 87 6.5 NR 0 NR NR NR NR 0 
Collins 2011 Control 73 6 NR NR NR NR NR NR NR 
Collins 2011 HET 72 6 NR NR NR NR NR NR NR 
Crowther 2012 SET 11 6 NR NR NR NR NR NR NR 
Crowther 2012 Control 11 6 NR NR NR NR NR NR NR 
Spafford 2014 SET 28 3 0 NR NR NR NR NR 0 
Spafford 2014 HET 24 3 1 NR NR NR NR NR 1 
Dawson 2000 Cilostazol 227 6 NR NR NR NR NR NR 2 
Dawson 2000 Control 239 6 NR NR NR NR NR NR 1 
Fakhry 2015 SET_ER 106 12 NR NR NR NR NR 0 1 
Fakhry 2015 SET 106 12 NR NR NR NR NR 2 3 
Gardner 2001 SET 31 6 NR NR NR NR NR NR NR 
Gardner 2001 Control 30 6 NR NR NR NR NR NR NR 
Gardner 2014 SET 60 3 NR 1 NR 0 NR NR NR 
Gardner 2014 HET 60 3 NR 0 NR 1 NR NR NR 
Gardner 2014# Control 60 3 1 1 NR 0 NR NR NR 





Gardner 2012 Control 36 6 NR NR NR 
Gardner 2011 HET 40 3 1 1 NR 1 NR NR NR 
Gardner 2011 SET 40 3 0 1 NR 0 NR NR NR 
Gardner 2011 Control 39 3 0 1 NR 1 NR NR NR 
Hobbs 2006 Control 7 6 NR NR NR NR NR NR NR 
Hobbs 2006 ER 9 6 NR NR NR NR NR NR NR 
Hobbs 2006 SET 7 6 NR NR NR NR NR NR NR 








Hobbs 2007 Cilostazol 9 6 NR NR NR NR NR NR NR 
Hobbs 2007 Control 9 6 NR NR NR NR NR NR NR 
Hodges 2008 SET 14 3 NR NR NR NR NR NR NR 
Hodges 2008 Control 14 3 NR NR NR NR NR NR NR 
Kakkos 2005 HET 10 12 NR NR NR NR NR NR 0 
Kakkos 2005 SET 12 12 NR NR NR NR NR NR 1 
Kruidenier 2011 ER 35 6 NR NR NR 2 NR NR NR 
Kruidenier 2011 SET_ER 35 6 NR NR NR 0 NR NR NR 
Lamberti 2016 HET 18 4 NR NR NR NR NR NR NR 
Lamberti 2016 ER 9 4 NR NR NR NR NR NR NR 
Novakovic 2019 SET 12 4.5 NR NR NR NR NR NR NR 
Novakovic 2019 Control 12 4.5 NR NR NR NR NR NR NR 
Mauer 2015 SET 16 3 NR NR NR NR NR NR NR 
Mauer 2015 Control 7 3 NR NR NR NR NR NR NR 
Mays 2015 Control 10 3.5 NR NR NR NR NR NR NR 
Mays 2015 HET 10 3.5 NR NR NR NR NR NR NR 
Mika 2005 SET 49 3 NR NR NR NR NR NR NR 
Mika 2005 HET 49 3 NR NR NR NR NR NR NR 
Miika 2011 SET 34 3 NR NR NR NR NR NR NR 
Miika 2011 Control 34 3 NR NR NR NR NR NR NR 
Sandercock 2007 SET 13 3 NR NR NR 1 NR NR NR 
Sandercock 2007 HET 15 3 NR NR NR 0 NR NR NR 
Sandercock 2007 Control 15 3 NR NR NR 0 NR NR NR 
Schlager 2011 SET 20 12 0 NR NR NR NR NR 0 
Schlager 2011 Control 20 12 1 NR NR NR NR NR 1 
Stewart 2008 SET 30 6 NR 1 NR 1 NR NR 1 
Stewart 2008 HET 30 6 NR 1 NR 0 NR NR 0 
Zwierska 2005 SET 37 6 NR NR NR NR NR NR 
3 

















SET 45 24 NR NR NR NR 2 
Greenhalgh 
2008b 
SET_ER 19 24 NR 
2* 
NR NR 0 NR 1 
Greenhalgh 
2008b 
SET 15 24 NR NR NR 0 NR 2 
Cheetham 2004 HET 30 12 NR NR NR NR NR NR 2 
Cheetham 2004 SET 29 12 NR NR NR NR NR NR 2 
O'Donnell 2009^ Cilostazol 39 6 NR NR NR NR NR NR NR 
O'Donnell 2009^ Control 41 6 NR NR NR NR NR NR NR 
Strandness 2002 Cilostazol 133 6 NR NR NR NR NR NR 2 
Strandness 2002 Control 128 6 NR NR NR NR NR NR 0 
Tew 2015 Control 9 1.5 NR 0 NR NR NR NR NR 
Tew 2015 HET 14 1.5 NR 1 NR NR NR NR NR 
Tsai 2002 SET 27 3 NR NR NR NR NR NR NR 
Tsai 2002 Control 26 3 NR NR NR NR NR NR NR 
Duscha 2018 HET 10 3 NR NR NR NR NR NR NR 
Duscha 2018 Control 9 3 NR NR NR NR NR NR NR 
Bullinska 2016 SET 31 1.5 NR NR NR NR NR NR NR 
Bullinska 2016 HET 21 1.5 NR NR NR NR NR NR NR 
Girold 2017 SET 21 1 NR NR NR NR NR NR NR 
Girold 2017 HET 21 1 NR NR NR NR NR NR NR 
* Group-wise data not available; ^ Cardiovascular adverse events reported together with other events, but individual event numbers were not 
provided; # Cerebral vascular accidents was considered as stroke; ER – Endovascular revascularization; HET – Home exercise therapy; SET – 









Figure S1. Markov Chain Monte Carlo simulation showing the trace plots and corresponding 
density plots during short-term follow-up.  
 
Convergence was achieved with higher iterations (100,000) and was suitable for the network 
model. HET – Home exercise therapy, SET – Supervised exercise therapy, ER – Endovascular 








Figure S2. Markov Chain Monte Carlo simulation showing the trace plots and 
corresponding density plots during moderate follow-up. 
 
Convergence was achieved with higher iterations (100,000) and was suitable for the network 
model. HET – Home exercise therapy, SET – Supervised exercise therapy, ER – Endovascular 








Figure S3. Markov Chain Monte Carlo simulation showing the trace plots and corresponding 
density plots during long-term follow-up. 
 
 
Convergence was achieved with higher iterations (100,000) and was suitable for the network 
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